Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · Jan 2016
Review Meta AnalysisAnti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in fetal life. Recently, researchers have attempted to use anti-VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. There is currently uncertainty regarding the safety and efficacy of these agents in preterm infants with ROP. ⋯ Further studies are needed to evaluate the effect of anti-VEGF agents on structural and functional outcomes in childhood and delayed systemic adverse effects such as myocardial dysfunction and adverse neurodevelopmental outcomes.
-
Cochrane Db Syst Rev · Jan 2016
ReviewWITHDRAWN: Psychological interventions to improve adherence to oral hygiene instructions in adults with periodontal diseases.
As this review is 10 years old, it has been withdrawn and will be superseded. A new protocol has been written and published: O'Malley L, Bonetti DL, Adair P, Jervøe‐Storm PM, Preshaw PM. Psychological interventions for improving adherence to oral hygiene instructions in adults with periodontal diseases (Protocol). ⋯ CD012049. The full review will be published in 2017. The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · Jan 2016
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs.
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID).To assess the effect of OST alone on the incidence of HCV infection among PWID. ⋯ How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID?How effective is OST alone for reducing HCV incidence among PWID?How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?
-
This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objective is to assess the role of iridotomy-compared with observation-in the prevention of visual field loss for individuals who have primary angle closure or primary angle-closure glaucoma in at least one eye. We will also examine the role of iridotomy in the prevention of elevated intraocular pressure (IOP) in individuals with narrow angles (primary angle-closure suspect) in at least one eye.